Laura Friedman had a good week on the press-release circuit. A $1 million-plus federal investment to replace a damaged Burbank reservoir, announced with the full fanfare of a.gov press release and picked up by financial data tracker Quiver Quantitative, is the kind of constituent-service win that fills a campaign mailer and clears the news cycle. What it doesn't do is explain why her three disclosed stock trades in the last 90 days are in Hologic and Abbott Laboratories. Two different worlds. The filings are public. Make of them what you make of them.
The News Peg: Water Money, Burbank Edition
This week, Friedman announced a federal investment topping $1 million to replace a damaged reservoir in Burbank, California. Her office framed it as a win for local water infrastructure. Quiver Quantitative picked it up the same day. Two stories in 24 hours. That's a minor news cycle by Washington standards, but it's enough to put her name in front of readers.
Friedman sits on the House Committee on Transportation and Infrastructure, including its Water Resources and Environment subcommittee. Water infrastructure is squarely in her lane. The reservoir grant tracks. This is what the committee is for.
Then there's the portfolio.
Three Trades, Neither of Them Near Water
Per her full disclosure record on Blind Trust, Friedman filed three trades in the last 90 days. All three are in healthcare, not infrastructure. Here's what the filings show:
- March 24, 2026: An exchange of Abbott Laboratories (ABT) stock, $1,000-$15,000 range.
- April 8, 2026: An exchange of Hologic (HOLX) stock, $1,000-$15,000 range.
- April 8, 2026: A sale of Hologic (HOLX) stock, $1,000-$15,000 range.
Hologic makes diagnostic imaging equipment and women's health products. Abbott Laboratories is a diversified medical device and diagnostics company. Neither has obvious surface-level exposure to Burbank reservoirs or federal water grants.
The dollar ranges are modest. The STOCK Act's disclosure brackets are wide, and $1K-$15K can mean a lot of things. But the trades exist. They're in the public record. And they have nothing to do with what Friedman has been talking about in her press releases this week.
The Alpha Record: One Scored Trade, Not Flattering
Blind Trust's alpha model has scored one of these three trades so far. The Abbott Laboratories exchange from March 24 clocked in at negative 15.9 percent over the subsequent 30 days, measured against the S&P 500. That's the full scored sample: zero positive outcomes out of one scored trade. Mean 30-day alpha: minus 15.9 percent.
One trade is one data point. Drawing a trend line through it would be editorial malpractice. But it's the number that exists, and the number is not good.
There's no committee overlap flagged on any of these trades. Friedman's committees cover Transportation and Infrastructure and Science, Space, and Technology. Medical devices and women's diagnostics don't fall under either remit. The Hologic and Abbott trades are just trades, nothing more sinister in the filing architecture.
The Floor Votes: Banking, Not Biotech
Friedman's most recent floor votes tell a different story from both her trades and her press releases. On May 20, she voted Yea on four separate bills in a single session: the American Access to Banking Act, the Community Bank Deposit Access Act of 2025, the Keeping Deposits Local Act, and, for historical texture, the 25th Anniversary of 9/11 Commemorative Coin Act. All passed.
Banking access legislation. On the same day. Three separate bills.
Banking regulation belongs to Financial Services, not Transportation and Infrastructure. Friedman voting on these bills is floor business, not committee oversight. There's no special-insight angle here, and we're not suggesting one. Members vote on the full calendar. That's the job.
She also voted Nay on the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act of 2026, both of which passed anyway on May 21. On June 11, she voted Nay on a FISA surveillance extension, which failed.
None of these floor votes map to her disclosed trades. The overlap table is empty. Stated plainly: Blind Trust has flagged zero vote-trade timing overlaps for Friedman in the current window.
The Bluesky Signal
One post on Bluesky is circulating about Friedman this week, unrelated to the reservoir grant. It concerns her confrontation with the Republican Energy Secretary over the decision to reopen an offshore pipeline that regulators determined was not ready, originally shut down following a major oil spill. That's Transportation and Infrastructure Committee territory. That's her lane. The social conversation there's about oversight, not portfolios.
The pipeline story and the reservoir grant together paint a picture of a member who is, at minimum, doing the visible work of her committees. She's on Water Resources. She's apparently berating Cabinet officials about pipelines. The press-release machine is running.
Whether the portfolio reflects any of that's a question the filings don't answer and we're not going to answer for them.
The Mismatch Worth Naming
Here's the Venn diagram: Friedman's public identity this week is water infrastructure, offshore pipeline safety, and constituent services in Burbank. Her committee assignments are Transportation and Infrastructure and Science, Space, and Technology. Her disclosed trades in the last 90 days are in a women's health diagnostics company and a diversified medical device manufacturer.
Those circles don't overlap.
There's no rule that a member's portfolio has to mirror their committee work. Members are required to disclose. They are not required to divest, recuse, abstain, or explain. The STOCK Act produced a paper trail, not a constraint.
What the paper trail shows here is an unremarkable set of small-dollar healthcare trades by a member whose public-facing work is entirely elsewhere. The scored alpha is negative. The committee overlap is zero. The vote-trade overlap table is blank.
The receipts are public. Make of them what you make of them.